FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial underway
Disease control OngoingThis study looks at three different drug combinations for women with ovarian, fallopian tube, or primary peritoneal cancer that has returned and is no longer responding to platinum-based chemotherapy. The trial compares a standard chemotherapy drug (pegylated liposomal doxorubici…
Matched conditions: FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:27 UTC
-
New drug combo shows promise in ovarian cancer safety trial
Disease control OngoingThis early-phase study tested adding the experimental drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) for people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to find the safest dose and check for side effec…
Matched conditions: FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New hope for Hard-to-Treat ovarian cancer: targeted drug combo under study
Disease control OngoingThis study tests whether a new drug combination (bevacizumab plus anetumab ravtansine) works better than standard chemotherapy (bevacizumab plus paclitaxel) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatme…
Matched conditions: FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis study compares two treatments for women with ovarian, fallopian tube, or peritoneal cancer that has come back after initial therapy. One group gets olaparib alone, the other gets olaparib plus tremelimumab. Olaparib blocks cancer cells from repairing themselves, while tremel…
Matched conditions: FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New combo aims to outsmart Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …
Matched conditions: FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
Ovarian cancer drug study aims to unlock DNA secrets before surgery
Knowledge-focused OngoingThis early-phase study is testing a drug called adavosertib in women with advanced ovarian, fallopian tube, or peritoneal cancer before they have surgery to remove tumors. The goal is to see how the drug changes the DNA of cancer cells, which may help doctors plan more effective …
Matched conditions: FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC